Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single-arm Phase II Trial of the Addition of Niraparib to Anti-PD-L1 Antibody Maintenance in Patients With SLFN11-positive, Extensive-disease Small Cell Lung Cancer.

NCT05718323 is registered in ClinicalTrials.gov with ETOP IBCSG Partners Foundation as lead sponsor.

NCT NCT05718323
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05718323 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single-arm Phase II Trial of the Addition of Niraparib to Anti-PD-L1 Antibody Maintenance in Patients With SLFN11-positive, Extensive-disease Small Cell Lung Cancer.
Lead sponsor
ETOP IBCSG Partners Foundation
Phase
Phase 2
Overall status
Recruiting
Start date
December 20, 2023
Completion date
June 30, 2027
Enrollment
44 (estimated)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

sclc,extensive stage, slfn11-positive